Chris Silva is the Chief Executive Officer of Allied Minds (LSE: ALM). Since 2006, he has grown Allied Minds to become a leading U.S. innovative science and technology development and commercialization company.
Ben Askew, PhD
Ben Askew is Vice President of Research at SciFluor Life Sciences and brings more than 20 years of experience in senior research positions in the biotechnology and pharmaceutical industries. He has specialized in building high functioning medicinal chemistry organizations, defining early IP and long-term R&D strategy, and leading NCE discovery programs.
Carl P. Decicco, PhD
Carl is the Head of Discovery at BMS and is responsible for the discovery and advancement of drug candidates for clinical studies. He also has oversight of the Drug Safety Evaluation team that provides supporting studies for all levels of clinical investigation.
Bruce D. Car, PhD
Bruce has been with BMS and its legacy companies for 22 years, working across all therapeutic areas and drug modalities. In 2010, Bruce extended previous responsibilities to include Discovery Metabolism, Biotransformation, Pharmacokinetics, Analytical Sciences, Toxicology, and Pharmaceutics as Vice President, PCO.
Catherine D. Strader, PhD
Catherine Strader has more than 25 years of pharmaceutical R&D experience, with expertise ranging from the selection of molecular targets through clinical proof of concept. She has held executive leadership positions at both Merck and Schering-Plough, and has guided more than 50 compounds through drug discovery and development.